Johnson & Johnson's first-quarter pharmaceutical sales jump 10%
This article was originally published in Scrip
Executive Summary
Johnson & Johnson reported higher first-quarter sales boosted by gains from newer drugs such as Zytiga for prostate cancer as well as established treatments for schizophrenia, psoriasis and rheumatoid arthritis.